Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 11/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 3/20 | 1.00 |
| ▸ | SLC10A2 | Q12908 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.80 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.80 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.80 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | VDR | P11473 | 1/20 | 0.78 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.76 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycoursodeoxycholic Acid SCHEMBL20204267 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL13851608 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL11962429 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL28793575 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL9151495 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL12917601 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL59881 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL935341 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL10694925 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL1219678 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1735 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260139227-A1 | ADIPOSE-DERIVED REGENERATIVE CELL PREPARATIONS | BLUE CELL THERAPEUTICS APS (DK) | 2026-05-21 | — | — | US | claimed |
| US-12569502-B2 | Use of bile acids and derivatives thereof in preparation of GPR39 agonist | PEKING UNIVERSITY (CN) | 2026-03-10 | — | — | US | claimed |
| EP-4701625-A2 | FORMULATION OF THERAPEUTIC AGENTS FOR IMPROVED PERMEATION | Vivtex Corporation (US) | 2026-03-04 | — | — | EP | claimed |
| EP-4262876-B1 | COVALENTLY MODIFIED ANTIGENS FOR IMPROVED IMMUNE RESPONSE AND/OR STABILITY | DEFENCE THERAPEUTICS INC (CA) | 2026-02-25 | — | — | EP | claimed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| EP-4638478-A1 | COVALENTLY-MODIFIED STEROID ACID-PEPTIDES HAVING ENHANCED STABILITY AND/OR BIOLOGICAL ACTIVITY | Defence Therapeutics Inc. (CA) | 2025-10-29 | — | — | EP | claimed |
| US-20250273338-A1 | BIOMARKERS FOR DETECTING COLORECTAL CANCER OR COLORECTAL ADENOMA AND METHODS THEREOF | Precogify Pharmaceutical China Co., Ltd. (CN) | 2025-08-28 | — | — | US | claimed |
| US-20250251371-A1 | Method for Identifying Calculus Bovis and Substitute Thereof, and Use Thereof | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2025-08-07 | — | — | US | claimed |
| US-12350346-B2 | Conjugates enhancing total cellular accumulation | DEFENCE THERAPEUTICS INC. (CA) | 2025-07-08 | — | — | US | claimed |
| WO-2001012155-A1 | COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2001-02-22 | — | — | WO | claimed |
| WO-2001009163-A2 | IMPROVEMENT OF PEPTIDE TRANSPORT BY CONJUGATION WITH BILE ACIDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2001-02-08 | — | — | WO | claimed |
| WO-2001001960-A1 | CLEAR OIL-CONTAINING PHARMACEUTICAL COMPOSITIONS | LIPOCINE, INC. (US) | 2001-01-11 | — | — | WO | claimed |
| WO-2000050007-A1 | COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF HYDROPHOBIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2000-08-31 | — | — | WO | claimed |
| US-6040188-A | MEASURING HYDROCARBON CONTAMINANTS IN SOIL BY MIXING SAMPLE WITH MIXTURE OF LIPIDS AND BILE SALTS, FORMING MICELLES; ALLOW SAMPLE-LIPID-BILE SALT MIXTURE COMPOSITION TO SEPARATE INTO LIQUID PHASE AND SOLID PHASE; MEASURE CONTAMINANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-03-21 | — | — | US | claimed |
| EP-0910411-A1 | HYDROPHOBIC PREPARATIONS CONTAINING MEDIUM CHAIN MONOGLYCERIDES | Cortecs (UK) Limited (GB) | 1999-04-28 | — | — | EP | claimed |
| WO-1998000169-A1 | HYDROPHOBIC PREPARATIONS CONTAINING MEDIUM CHAIN MONOGLYCERIDES | CORTECS (UK) LIMITED) (GB) | 1998-01-08 | — | — | WO | claimed |
| EP-0813421-A1 | LIQUID FORMULATIONS FOR PROTEINIC PHARMACEUTICALS COMPRISING AT LEAST 2 ABSORPTION ENHANCERS | MODI, Pankaj (CA) | 1997-12-29 | — | — | EP | claimed |
| US-5653987-A | FOR ORAL DELIVERY OF INSULIN | MODI PANKAJ (CA) | 1997-08-05 | — | — | US | claimed |
| WO-1996036352-A1 | LIQUID FORMULATIONS FOR PROTEINIC PHARMACEUTICALS COMPRISING AT LEAST 2 ABSORPTION ENHANCERS | MODI PANKAJ (CA) | 1996-11-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139227-A1 | ADIPOSE-DERIVED REGENERATIVE CELL PREPARATIONS | CXCL12, FGF2, FABP4 | GPBAR1 3626/4885NR1H4 3664/4885ABCB11 2764/4885 |
| US-12569502-B2 | Use of bile acids and derivatives thereof in preparation of GPR39 agonist | GPR39, GPBAR1, GPR119 | GPBAR1 2/4885NR1H4 8/4885ABCB11 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.